The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

GMALL B-ALL/NHL 2002 Protocol Achieves High Rates of Sustained Response in High-Grade B-Cell Lymphoma

  • By

  • Silvia Ferrari

  • Francesco Ballardini

  • Andrea Rossi

  • Anna Grassi

  • Chiara Pavoni

  • Monica Rondi

  • Paolo Fruscella

  • Andrea Gianatti

  • Giuseppe Gritti

  • Anna Maria Barbui

  • Federico Lussana

  • Alessandro Rambaldi

  • October 9, 2026

Share

  • 1

    This single-center cohort included 53 patients with high-grade B-cell lymphoma treated with the GMALL B-ALL/NHL 2002 protocol from 2011 to 2023.

  • 2

    At end of treatment, 42 patients (79.2%) achieved metabolic complete response, and 7 (13.2%) achieved partial response.

  • 3

    Six-year progression-free survival was 72% overall, 83% for HGBCL, NOS, and 49% for double-hit lymphoma.

  • 4

    Six-year overall survival was 76% overall, 86% for HGBCL, NOS, and 56% for double-hit lymphoma.

  • 5

    Adverse reactions occurred in 25 patients; febrile neutropenia affected 12, sepsis 4, and mucositis 9, with no chemotherapy-attributable deaths during treatment.

Original Source(s)

The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma

  • by Silvia Ferrari, Francesco Ballardini, Andrea Rossi, Anna Grassi, Chiara Pavoni, Monica Rondi, Paolo Fruscella, Andrea Gianatti, Giuseppe Gritti, Anna Maria Barbui, Federico Lussana, Alessandro Rambaldi

  • October 9, 2026

Related Content

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

  • October 12, 2026

  • 3 min
Daily-life dynamics of general and cognitive fatigue in childhood cancer survivors: An experience sampling and wearable study

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

  • October 15, 2026

  • 1 min